 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Bupropion To Prevent Relapse in People Who Quit Cigarette Smoking
18 September 2001 | Volume 135 Issue 6 | Page S40
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation. A Randomized, Controlled Trial." It is in the 18 September 2001 issue of Annals of Internal Medicine (volume 135, pages 423-433). The authors are JT Hays, RD Hurt, NA Rigotti, R Niaura, D Gonzales, MJ Durcan, DPL Sachs, TD Wolter, AS Buist, JA Johnston, and JD White.
What is the problem and what is known about it so far?
The difficult task of quitting cigarette smoking has been made somewhat easier by the use of nicotine replacement therapy and non-nicotine medications, such as bupropion. Even so, 70% to 80% of people who are able to stop smoking begin smoking again within 6 to 12 months. Although bupropion has been shown to be effective for short-term avoidance of smoking, no one knows if prolonged treatment can prevent a smoking relapse.
Why did the researchers do this particular study?
To find out if smoking relapses can be prevented by prolonged treatment with bupropion.
Who was studied?
784 healthy smokers who were motivated to quit were enrolled at five major medical centers in the United States.
How was the study done?
All participants were given sustained-release bupropion (but not nicotine replacement) for 7 weeks. Participants who reported complete avoidance of smoking during the 7th week and who showed no bodily evidence of nicotine were randomly assigned to one of two treatment groups: For the next 45 weeks, half of the participants continued to receive bupropion while the other half received an identical-appearing placebo pill. Neither the participants nor the evaluators were told which type of pill each participant was receiving. At monthly meetings, participants were questioned to see if they had remained free of cigarette smoking. To confirm reports of smoking abstinence, testing for evidence of nicotine in the body was done in participants who said that they had been free of cigarette smoking. After 1 year, treatment was stopped in both the bupropion and the placebo groups, but follow-up to detect smoking relapse continued for another year to evaluate the long-term effect of having received bupropion. Weight change over time was also recorded.
What did the researchers find?
Of the 784 participants, 461 had quit smoking by the 7th week and 429 were assigned to receive bupropion or placebo for the next 45 weeks. After 45 weeks, 55.1% of the bupropion group had abstained from smoking versus 42.3% of the placebo group. The relapse rate in the two groups remained different for up to 6 months after medication was stopped. However, 1 year after medication was stopped, the difference had disappeared (41.6% of the bupropion group and 40.0% of the placebo group were free of smoking). Weight gain was greater in the placebo group, and this difference remained until the end of the study. Side effects were as common in placebo recipients as in bupropion recipients.
What were the limitations of the study?
The research participants may not be representative of all smokers, and therefore results may differ in the general population. Many participants dropped out before the end of the study.
What are the implications of the study?
Bupropion seems effective in increasing the quit rate among cigarette smokers. As long as bupropion is continued, the smoking relapse rate remains lower than in persons treated with placebo, but the effect does not continue for very long after the medication is stopped. Bupropion appears to limit the weight gain associated with quitting cigarette smoking.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. B. Steinberg, A. C. Schmelzer, D. L. Richardson, and J. Foulds The Case for Treating Tobacco Dependence as a Chronic Disease Ann Intern Med, April 1, 2008; 148(7): 554 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rovina, I. Nikoloutsou, E. Dima, M. Michailidou, C. Roussos, and C. Gratziou Smoking cessation treatment in a real-life setting: the Greek experience Therapeutic Advances in Respiratory Disease, December 1, 2007; 1(2): 93 - 104. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Le Foll MD PhD and T. P. George MD Treatment of tobacco dependence: integrating recent progress into practice Can. Med. Assoc. J., November 20, 2007; 177(11): 1373 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Leeman, C. J. Huffman, and S. S. O'Malley Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review Alcohol Alcohol., May 1, 2007; 42(3): 196 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Tonnesen, L. Carrozzi, K. O. Fagerstrom, C. Gratziou, C. Jimenez-Ruiz, S. Nardini, G. Viegi, C. Lazzaro, I. A. Campell, E. Dagli, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy Eur. Respir. J., February 1, 2007; 29(2): 390 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Varenicline (Chantix) for Tobacco Dependence Obstet. Gynecol., January 1, 2007; 109(1): 192 - 193. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Schroeder and H. C. Sox Trials that Matter: Varenicline: A Designer Drug to Help Smokers Quit. Ann Intern Med, November 21, 2006; 145(10): 784 - 785. [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Jorenby, J. T. Hays, N. A. Rigotti, S. Azoulay, E. J. Watsky, K. E. Williams, C. B. Billing, J. Gong, K. R. Reeves, and for the Varenicline Phase 3 Study Group Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA, July 5, 2006; 296(1): 56 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tonstad, P. Tonnesen, P. Hajek, K. E. Williams, C. B. Billing, K. R. Reeves, and for the Varenicline Phase 3 Study Group Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA, July 5, 2006; 296(1): 64 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Lancaster, P. Hajek, L. F. Stead, R. West, and M. J. Jarvis Prevention of Relapse After Quitting Smoking: A Systematic Review of Trials. Arch Intern Med, April 24, 2006; 166(8): 828 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. L. Sachs Tobacco dependence treatment: time to change the paradigm. Chest, April 1, 2006; 129(4): 836 - 839. [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Berrettini and C. E. Lerman Pharmacotherapy and Pharmacogenetics of Nicotine Dependence Am J Psychiatry, August 1, 2005; 162(8): 1441 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Holt, C Timu-Parata, S Ryder-Lewis, M Weatherall, and R Beasley Efficacy of bupropion in the indigenous Maori population in New Zealand Thorax, February 1, 2005; 60(2): 120 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lerman, F. Patterson, and W. Berrettini Treating Tobacco Dependence: State of the Science and New Directions J. Clin. Oncol., January 10, 2005; 23(2): 311 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Hall, G. L. Humfleet, V. I. Reus, R. F. Munoz, and J. Cullen Extended Nortriptyline and Psychological Treatment for Cigarette Smoking Am J Psychiatry, November 1, 2004; 161(11): 2100 - 2107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Simon, C. Duncan, T. P. Carmody, and E. S. Hudes Bupropion for Smoking Cessation: A Randomized Trial Arch Intern Med, September 13, 2004; 164(16): 1797 - 1803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J S Haas, C P Kaplan, D Barenboim, P Jacob 3rd, and N L Benowitz Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use Tob. Control, March 1, 2004; 13(1): 52 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Tonstad, C Farsang, G Klaene, K Lewis, A Manolis, A.P Perruchoud, C Silagy, P.I van Spiegel, C Astbury, A Hider, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study Eur. Heart J., May 2, 2003; 24(10): 946 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Hurt, J. E. Krook, I. T. Croghan, C. L. Loprinzi, J. A. Sloan, P. J. Novotny, C. G. Kardinal, J. A. Knost, M. T. Tirona, F. Addo, et al. Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking J. Clin. Oncol., March 1, 2003; 21(5): 914 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Fiore, D. K. Hatsukami, and T. B. Baker Effective Tobacco Dependence Treatment JAMA, October 9, 2002; 288(14): 1768 - 1771. [Full Text] [PDF]
|
|
|
|
|
|
A. C. DeGraff Jr Pharmacologic Therapy for Nicotine Addiction Chest, August 1, 2002; 122(2): 392 - 394. [Full Text] [PDF]
|
|
|
|
 |
|
 Can Bupropion Prevent Relapse After Smoking Cessation? Journal Watch Psychiatry, November 15, 2001; 2001(1115): 9 - 9. [Full Text]
|
|
|
|
 |
|
 Can Bupropion Prevent Relapse After Smoking Cessation? Journal Watch (General), September 25, 2001; 2001(925): 2 - 2. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
